Mood disorders and complementary and alternative medicine: A literature review

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 639-658

  Qureshi, Naseem Akhtar ^a   Mohammed, Abdullah ^a   Al Bedah, ^b  

^a Sulaimania Medical Complex   (Saudi Arabia)

^b Ministry of Health ^*  (Saudi Arabia)

Author keywords

Ayurveda; Complementary and alternative medicine; Homeopathy; Integrative medicine; Mood disorders

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETYLCYSTEINE; CHOLINE; CITALOPRAM; COLECALCIFEROL; DOCOSAHEXAENOIC ACID; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; ICOSAPENTAENOIC ACID; IMIPRAMINE; INOSITOL; KIRA; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PAROXETINE; PLACEBO; PRASTERONE; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VITAMIN B COMPLEX; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ACUPUNCTURE; ALTERNATIVE MEDICINE; BIPOLAR DEPRESSION; COMORBIDITY; DEPRESSION; DIET SUPPLEMENTATION; DISEASE SEVERITY; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; HERB; HOMEOPATHY; HUMAN; INTEGRATIVE MEDICINE; MAJOR DEPRESSION; MALE; MANIA; MEDITATION; MOOD DISORDER; PROGNOSIS; PSYCHOTHERAPY; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; SLEEP DEPRIVATION; SOCIAL PSYCHOLOGY; UNSPECIFIED SIDE EFFECT; YOGA;

EID: 84877941675     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S43419     Document Type: Review

References (218)

1. Herman PM, Poindexter BL, Witt CM, Eisenberg DM. Are complementary therapies and integrative care cost-effective? A systematic review of economic evaluations. BMJ Open. 2012;2:e001046.
2. World Health Organization. World Mental Health Survey Consortium: prevalence, severity and unmet need for treatment of mental disorders in WHO world mental health surveys. JAMA. 2004;291:2581-2590.
3. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
4. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35:1-14.
5. Fandiño-Losada A, Forsell Y, Lundberg I. Demands, skill discretion, decision authority and social climate at work as determinants of major depression in a 3-year follow-up study. Int Arch Occup Environ Health. July 4, 2012. Epub ahead of print.
6. Nordentoft M. Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups. Dan Med Bull. 2001;54:306-369.
7. Freeman EJ, Colpe LJ, Strine TW, et al. Public health surveillance for mental health. Prev Chronic Dis. 2010;7:A17.
8. Lauterbach E, Rumpf HJ, Ahrens B, et al. Assessing dimensional and categorical aspects of depression: validation of the AMDP Depression Scale. Eur Arch Psychiatry Clin Neurosci. 2005;255:15-19.
9. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;9:CD008012.
10. National Health Service. Depression in adults with a chronic physical health problem. NICE clinical guideline 91; 2010. Available from: http://www.nice.org.uk/guidance/CG91. Accessed March 20, 2013.
11. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by neuroinflammatory and oxidative and nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32:7-24.
12. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6: 369-388.
13. Al-Harbi KS, Qureshi NA. Neuromodulation therapies and treatmentresistant depression. Med Devices (Auckl). 2012;5:53-65.
14. American Psychiatric Association. Diagnostic and Statistical Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 1994.
15. World Health Organization. International Classification of Diseases-10. Geneva, Switzerland: World Health Organization; 1990.
16. Walpole SC, McMillan D, House A, Cottrell D, Mir G. Interventions for treating depression in Muslim patients: a systematic review. J Affect Disord. 2013;145:11-20.
17. Bartolomucci A, Leopardi R. Stress and depression: preclinical research and clinical implications. PLoS One. 2009;4:e4265.
18. Fava M, Farabaugh AH, Sickinger AH, et al. Personality disorders and depression. Psychol Med. 2002;32:1049-1057.
19. Ito N, Hori A, Yabe T, et al. Involvement of neuropeptide y signaling in the antidepressant-like effect and hippocampal cell proliferation induced by kososan, a kampo medicine, in the stress-induced depression-like model mice. Biol Pharm Bull. 2012;35:1775-1783.
20. Wolkowitz OM, Reus VI, Mellon SH. Of sound mind and body: depression, disease, and accelerated aging. Dialogues Clin Neurosci. 2011;13:25-39.
21. Dacher E. The development of an integrated medical model: toward a postmodern medicine. In: Micozzi MS, editor. Fundamentals of Complementary and Alternative Medicine. New York, NY: Churchill Livingstone; 2001.
22. Sarris J. Clinical depression: an evidence-based integrative complementary medicine treatment model. Altern Ther Health Med. 2011;17:26-37.
23. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61:714-719.
24. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64 Suppl 13:18-25.
25. Baghai TC, Moller HJ, Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des. 2006;12:503-515.
26. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
27. Bambauer KZ, Adams AS, Zhang F, et al. Physician alerts to increase antidepressant adherence: fact or fiction? Arch Intern Med. 2006;166: 498-504.
28. Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol. 2006;20 Suppl 3:29-34.
29. Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J Psychopharmacol. 2006;20 Suppl 3:19-28.
30. Department of Ayush, Ministry of Health and Family Welfare. Available from: http://indianmedicine.nic.in/. Accessed October 10, 2012.
31. Perron BE, Jarman CN, Kilbourne AM. Access to conventional mental health and medical care among users of complementary and alternative medicine with bipolar disorder. J Nerv Ment Dis. 2009;197:287-290.
32. Jarman CN, Perron BE, Kilbourne AM, Teh CF. Perceived treatment effectiveness, medication compliance, and complementary and alternative medicine use among veterans with bipolar disorder. J Altern Complement Med. 2010;16:251-255.
33. Nahas R, Sheikh O. Complementary and alternative medicine for the treatment of major depressive disorder. Can Fam Physician. 2011;57: 659-663.
34. Muskin PR. Introduction: herbs and hermeneutics. In: Complementary and Alternative Medicine and Psychiatry. Arlington, VA: American Psychiatric Press Inc; 2005.
35. LaPatra J. Healing: The Coming Revolution in Holistic Medicine. New York, NY: McGraw-Hill; 1978.
36. Al-Bedah A. Public perspective: information and insights in complementary and alternative medicine. Oman Med J. 2012;27:20.
37. Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord. 2009;117 Suppl 1:S54-S64.
38. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010;71:669-681.
39. Hoenders HJ, Appelo MT, van den Brink EH, Hartogs BMA, de Jong JTVM. The Dutch Complementary and Alternative Medicine (CAM) protocol: to ensure safe and effective use of CAM within Dutch mental health care. J Complement Altern Med. 2011;17:1197-1201.
40. Gupta S, Chauhan D, Mehla K, Sood P, Nair A. An overview of nutraceuticals: current scenario. J Basic Clin Pharm. 2010;1:55-62.
41. Bottiglieri T. S-Adenosyl-L-methionine (SAMe) from the bench to the bedside- molecular basis of pleiotrophic molecule. Am J Clin Nutr. 2002;76:1151S-1157S.
42. Brown RP, Gerbarg PL, Bottiglieri T. S-Adenosylmethionine (SAMe) for depression: biochemical and clinical evidence. Psychiatr Ann. 2002;32:29-44.
43. Carpenter DJ. St John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit? Altern Med Rev. 2011;16:17-39.
44. Papakostas GI, Cassiello CF, Iovieno N. Folates and s-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012;57:406-413.
45. Freeman MP, Mischoulon D, Tedeschini E, et al. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010;71: 682-688.
46. Alpert JE, Papakostas G, Mischoulan D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24: 661-664.
47. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167: 942-948.
48. Ernst E. Complementary medicine. Curr Opin Rheumatol. 2003;15: 151-155.
49. Grassetto M, Varratto A. Primary fibromyalgia is responsive to S-adenosyl-L-methionine. Curr Ther Res. 1994;55:797-806.
50. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver diseases. Am J Clin Nutr. 2002;76:S1183-S1187.
51. Aleynik SI, Lieber CS. Polienylphosphatidylcholine corrects the alcoholinduced hepatic oxidative stress by restoring s-adenosylmethionine. Alcohol Alcohol. 2003;38:208-212.
52. Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-adenosyl- L-methionine improves depression in patients with Parkinson's disease in an open label clinical trial. Mov Disord. 2000;15:1225-1229.
53. Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak SE. S-adenosyl- L-methionine (SAMe) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry. 2004;4:38.
54. Cerutti R, Sichel MP, Perin M, et al. Psychological distress during puerperium: a novel therapeutic approach using S-adenosylmethionine. Curr Ther Res. 1993;53:707-716.
55. Surtees R, Hyland K. A method for the measurement of S-adenosylmethionine in small volume samples of cerebrospinal fluid or brain using high-performance liquid chromatography-electro chemistry. Ann Biochem. 1989;181:333-335.
56. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012;3:1174-1178.
57. Brown RP, Gerberg PL, Muskin PR, editors. Mood disorders. In: How to Use Herbs, Nutrients and Yoga in Mental Health. New York, NY: WW Norton & Company; 2009.
58. El-Alfy AT, Abourashed EA, Matsumoto RR. Nature against depression. Curr Med Chem. 2012;19:2229-2241.
59. Iovieno N, Dalton ED, Fava M, Mischoulon D. Second-tier natural antidepressants: review and critique. J Affect Disord. 2011;130: 343-357.
60. Linde K, Ramirez G, Mulrow CD, Pauls A, Wesdenhammer W, Melchart D. St John's Wort for depression - an overview and metaanalysis of randomized clinical trials. BMJ. 1996;313:253-258.
61. Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30 Suppl 2:81-85.
62. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000;15:61-68.
63. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978-1986.
64. Gelenberg AJ, Shelton RC, Crits-Christoph P, et al. The effectiveness of St John's wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry. 2004;65:1114-1119.
65. No authors listed. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807-1814.
66. Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. 2005;255:40-47.
67. Moreno RA, Teng CT, Almeida KM, Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr. 2006;28:29-32.
68. Fava M, Alpert J, Nierenberg AA, et al. A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005;25:441-447.
69. Chen JA, Papakostas GI, Youn SJ, et al. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011;72:1669-1676.
70. Kasper S, Anghelescu IG, Szegedi A, Dienel A, Kieser M. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med. 2006;4:14.
71. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry. 2005;38:78-86.
72. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ. 2005;330:503.
73. Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin. 1999;15:33-37.
74. Singer A, Schmidt M, Hauke W, Stade K. Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. Phytomedicine. 2011;18:739-742.
75. Rapaport MH, Nierenberg AA, Howland R, Dording C, Schettler PJ, Mischoulon D. The treatment of minor depression with St John's Wort or citalopram: failure to show benefit over placebo. J Psychiatr Res. 2011;45:931-941.
76. Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause. 2007;14(3 Pt 1): 541-549.
77. Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009;11:710-727.
78. Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204-213.
79. Knüppel L, Linde K. Adverse effects of St John's wort: a systematic review. J Clin Psychiatry. 2004;65:1470-1479.
80. Thakor V, Leach MJ, Gillham D, Esterman A. The quality of information on websites selling St John's wort. Complement Ther Med. 2011;19:155-160.
81. Clauson KA, Santamarina ML, Rutledge JC. Clinically relevant safety issues associated with St John's wort product labels. BMC Complement Altern Med. 2008;8:42.
82. McCrea CE, Pritchard ME. Concurrent herb-prescription medication use and health care provider disclosure among university students. Complement Ther Med. 2011;19:32-36.
83. Edwards D, Heufelder A, Zimmermann A. Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-stress symptoms - results of an open-label study. Phytother Res. 2012;26:1220-1225.
84. Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010;17:481-493.
85. Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61: 343-348.
86. Chan SW. Panax ginseng, Rhodiola rosea and Schisandra chinensis. Int J Food Sci Nutr. 2012;63 Suppl 1:75-81.
87. Kelly GS. Rhodiola rosea: a possible plant adaptogen. Altern Med Rev. 2001;6:293-302.
88. van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol. 2009;122:397-401.
89. Dwyer AV, Whitten DL, Hawrelak JA. Herbal medicines, other than St John's wort, in the treatment of depression: a systematic review. Altern Med Rev. 2011;16:40-49.
90. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21:841-860.
91. Li LT, Wang SH, Ge HY, Chen J, Yue SW, Yu M. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med. 2008;14:841-846.
92. Rai V, Kattar P, Khatoon S, Rawat AKS, Mehrotra S. Heavy metal accumulation in some herbal drugs. Pharm Biol. 2001;39:384-387.
93. Hugget DB, Kahn IA, Allgood JC, Block DS, Schlenk D. Organochlorine pesticides and metals in select botanical dietary supplements. Bull Environ Contam Toxicol. 2001;66:150-155.
94. Ernst E, Coon JT. Heavy metals in traditional Chinese medicine: a systematic review. Clin Pharmacol Ther. 2001;70:497-504.
95. Rai V, Kakkar P, Singh J, Misra C, Kumar S, Mehrotra S. Toxic metals and organochlorine pesticides residue in single herbal drugs used in important Ayurvedic formulation- 'Dashmoola'. Environ Monit Assess. 2008;143:273-277.
96. Gasser U, Klier B, Kühn AV, Steinhoff B. Current findings on the heavy metal content in herbal drugs. Pharmeur Sci Notes. 2009;1: 37-50.
97. Sullivan J, Greenfield J, Cumberford G, Grant J, Stewart J. Extraction efficiencies of heavy metals in hydroethanolic solvent from herbs of commerce. J AOAC Int. 2010;93:496-498.
98. Rosecrans R, Dohnal JC. The effect of complimentary and alternative medicine products on laboratory testing. Semin Diagn Pathol. 2009;26:38-48.
99. Sadovsky R, Collins N, Tighe AP, Brunton SA, Safeer R. Patient use of dietary supplements: a clinician's perspective. Curr Med Res Opin. 2008;24:1209-1216.
100. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69:295-307.
101. Ellsworth-BowersER,CorwinEJ.Nutritionandthepsychoneuroimmunology of postpartum depression. Nutr Res Rev. 2012;25:180-192.
102. Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev. 1996;54:382-390.
103. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders. Clinical potential. Drugs. 1993;45:623-636.
104. Procter A. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatry. 1991;159:271-272.
105. Bell IR, Edman JS, Morrow FD, et al. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr. 1992;11:159-163.
106. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60:121-130.
107. Christensen H, Aiken A, Batterham PJ, et al. No clear potentiation of antidepressant medication effects by folic acid + vitamin B12 in a large community sample. J Affect Disord. 2011;130:37-45.
108. Walker JG, Mackinnon AJ, Batterham P, et al. Mental health literacy, folic acid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial. Br J Psychiatry. 2010;197:45-54.
109. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350: 2673-2681.
110. Haines ST, Park SK. Vitamin D supplementation: what's known, what to do, and what's needed. Pharmacotherapy. 2012;32:354-382.
111. Dumville JC, Miles JN, Porthouse J, Cockayne S, Sexon L, King C. Can vitamin D supplementation prevent winter-time blues? A randomized trial among older women. J Nutr Health Aging. 2006;10:151-153.
112. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008;264:599-609.
113. Kjærgaard M, Waterloo K, Wang CE, et al. Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial. Br J Psychiatry. 2012;201:360-368.
114. Bertone-Johnson ER, Powers SI, Spangler L, et al. Vitamin D supplementation and depression in the women's health initiative calcium and vitamin D trial. Am J Epidemiol. 2012;176:1-13.
115. Tariq MM, Streeten EA, Smith HA, et al. Vitamin D: a potential role in reducing suicide risk? Int J Adolesc Med Health. 2011;23: 157-165.
116. Hirashima F, Parow AM, Stoll AL, et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry. 2004;161:1922-1924.
117. Parker G, GibsonNA, Brotchie H, Heruc G, ReesAM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006; 163:969-978.
118. Rocha Araujo DM, Vilarim MM, Nardi AE. What is the effectiveness of the use of polyunsaturated fatty acid omega-3 in the treatment of depression? Expert Rev Neurother. 2010;10:1117-1129.
119. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72:1577-1584.
120. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol. 2012;32:61-64.
121. Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry. 2006;163:1100-1102.
122. McNamara RK, Hahn CG, Jandacek R, et al. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry. 2007;62:17-24.
123. Freeman MP, Hibbeln JR, Wisner KL, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967.
124. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:267-271.
125. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159:477-479.
126. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Räsänen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord. 2004;82:447-452.
127. Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 2012;32:699-703.
128. McNamara RK. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: current status, future directions, and dietary recommendations. Prostaglandins Leukot Essent Fatty Acids. 2009;81:223-231.
129. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry. 2003;160: 2222-2227.
130. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry. 2005;66:726-729.
131. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006;188:46-50.
132. Keck PE Jr, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60:1020-1022.
133. Osher Y, Belmaker RH. Omega-3 fatty acids in depression: a review of three studies. CNS Neurosci Ther. 2009;15:128-133.
134. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81-86.
135. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord. 2002;69:15-29.
136. Su KP, Huang SY, ChiuTH, et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69: 644-651.
137. Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, GelenbergAJ. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand. 2006;113:31-35.
138. Deligiannidis KM, Freeman MP. Complementary and alternative medicine for the treatment of depressive disorders in women. Psychiatr Clin North Am. 2010;33:441-463.
139. Lustyk MKB, Gerrish WG. Premenstrual syndrome and premenstrual dysphoric disorder: issues of quality of life, stress and exercise. In: Preedy V, Watson RR, editors. Handbook of Disease Burdens and Quality of Life Measures. Heidelberg, Germany: Springer Science + Business Media LLC; 2010.
140. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol. 2007;17:440-447.
141. Loo M, editor. Integrative Medicine for Children. St Louis, MO: Saunders Elsevier Inc; 2009.
142. Bogarapu S, Bishop JR, Krueger CD, Pavuluri MN. Complementary medicines in pediatric bipolar disorder. Minerva Pediatr. 2008;60: 103-114.
143. Frazier EA, Fristad MA, Arnold LE. Feasibility of a nutritional supplement as treatment for pediatric bipolar spectrum disorders. J Altern Complement Med. 2012;18:678-685.
144. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry. 1996;40:382-388.
145. Lyoo IK, Demopulos CM, Hirashima F, Ahn KH, Renshaw PF. Oral choline decreases brain purine levels in lithium-treated subjects with rapid-cycling bipolar disorder: a double-blind trial using proton and lithium magnetic resonance spectroscopy. Bipolar Disord. 2003;5: 300-306.
146. BenjaminJ,AgamG, Levine J,BersudskyY,KofmanO,BelmakerRH. Inositol treatment in psychiatry. Psychopharmacol Bull. 1995;31:167-175.
147. Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res. 2010;44:32-41.
148. Chengappa KN, Levine J, Gershon S, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2000;2: 47-55.
149. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210-216.
150. Back EE, Henning KJ, Kallenbach LR, Brix KA, Gunn RA, Melius JM. Risk factors for developing eosinophilia myalgia syndrome (EMS) among L-tryptophan users in New York. J Rheumatol. 1993;20: 666-672.
151. Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-Ltryptophan. Toxicol Lett. 2004;150:111-122.
152. Gijsman HJ, van Gerven JM, de Kam ML et al. Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol. 2002;22:183-189.
153. Smaga I, Pomierny B, Krzyzanowska W, et al. N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:280-287.
154. Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord. 2011;13:454-465.
155. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36:78-86.
156. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999;45:1533-1541.
157. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156:646-649.
158. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005;62:154-162.
159. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry. 2006;163:59-66.
160. Bloch M, Ish-Shalom S, Greenman Y, Klein E, Latzer Y. Dehydroepiandrosterone treatment effects on weight, bone density, bone metabolism and mood in women suffering from anorexia nervosa-a pilot study. Psychiatry Res. 2012;200:544-549.
161. Satow YE, Kumar PD, Burke A, Inciardi JF. Exploring the prevalence of Ayurveda use among Asian Indians. J Altern Complement Med. 2008;14:1249-1253.
162. Prathikanti S. Ayurvedic treatments. In: Lake J, Spiegel D, editors. Complementary and Alternative Treatments. Washington, DC: American Psychiatric Publishing; 2007.
163. Sharma H, Chandola HM, Singh G, Basisht G. Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease. Part 2 - Ayurveda in primary health care. J Altern Complement Med. 2007;13:1135-1150.
164. Ven Murthy MR, Ranjekar PK, Ramassamy C, Deshpande M. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: Ashwagandha. Cent Nerv Syst Agents Med Chem. 2010;10:238-246.
165. Shrestha BG, Takagi Y, Ishii T, Wadhwa R, Kaul SC. Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clin Cancer Res. 2007;13:2298-2306.
166. Maity T, Adhikari A, Bhattacharya K, Biswas S, Debnath PK, Maharana CS. A study on evaluation of antidepressant effect of imipramine adjunct with Aswagandha and Bramhi. Nepal Med Coll J. 2011;13:250-253.
167. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolyticantidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine. 2000;7:463-469.
168. [No authors listed]. Monograph. Withania somnifera. Altern Med Rev. 2004;9:211-214.
169. Rioux J. A complex, nonlinear dynamic systems perspective onAyurveda and Ayurvedic research. J Altern Complement Med. 2012;18:709-718.
170. Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs. 2010;19:1297-1307.
171. Posmontier B, Teitelbaum M. An Ayurvedic approach to postpartum depression. Holist Nurs Pract. 2009;23:201-214.
172. Bawden S. Running an NHS community homeopathy clinic - 10-year anniversary 2001-2011. Homeopathy. 2012;101:51-56.
173. Pilkington K, Kirkwood G, Rampes H, Fisher P, Richardson J. Homeopathy for depression: a systematic review of the research evidence. Homeopathy. 2005;94:153-163.
174. Mathie RT, Robinson TW. Outcomes from homeopathic prescribing in medical practice: a prospective, research-targeted, pilot study. Homeopathy. 2006;95:199-205.
175. Davidson JR, Crawford C, Ives JA, Jonas WB. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. J Clin Psychiatry. 2011;72:795-805.
176. Selhub E. Mind-body medicine for treating depression: using the mind to alter the body's response to stress. Alternative and Complementary Therapies. 2007;13:4-9.
177. Pilkington K, Kirkwood G, Rampes H, Richardson J. Yoga for depression: the research evidence. J Affect Disord. 2005;89:13-24.
178. Wood C. Mood change and perceptions of vitality: a comparison of the effects of relaxation, visualization and yoga. J R Soc Med. 1993;86:254-258.
179. Shannahoff-Khalsa DS. Kundalini yoga meditation techniques for the treatment of obsessive-compulsive and OC spectrum disorders. Brief Treat Crisis Interv. 2003;3:369-382.
180. Lavey R, Sherman T, Mueser KT, Osborne DD, Currier M, Wolfe R. The effects of yoga on mood in psychiatric inpatients. Psychiatr Rehabil J. 2005;28:399-402.
181. Weintraub A. Yoga for Depression: A Compassionate Guide to Relieve Suffering Through Yoga. New York, NY: Three Rivers Press; 2004.
182. Woolery A, Myers H, Sternlieb B, Zeltzer L. A yoga intervention for young adults with elevated symptoms of depression. Altern Ther Health Med. 2004;10:60-63.
183. Shapiro D, Cook IA, Davydov DM, Ottaviani C, Leuchter AF, Abrams M. Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome. Evid Based Complement Alternat Med. 2007;4:493-502.
184. Khumar SS, Kaur PKS. Effectiveness of Shavasana on depression in university students. Indian J Clin Psychol. 1993;20:82-87.
185. Tsang HW, Fung KM, Chan AS, Lee G, Chan F. Effect of a qigong exercise programme on elderly with depression. Int J Geriatr Psychiatry. 2006;21:890-897.
186. Janakiramaiah N, Gangadhar BN, NagaVenkatesha Murthy PJ, Harish MG, Subbakrishna DK, Vedamurthachar A. Antidepressant eff icacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine. J Affect Disord. 2000;57:255-259.
187. Brown RP, Gerberg PL. Sudarshan Kirya Yogic breathing in the treatment of stress, anxiety and depression: Part 1 Neurophysiologic model. J Altern Complement Med. 2005;11:189-201.
188. Brown RP, Gerberg PL. Sudarshan Kirya Yogic breathing in the treatment of stress, anxiety and depression: Part I1 Clinical applications and guidelines. J Altern Complement Med. 2005;11:711-717.
189. Bennett SM, Weintraub A, Khalsa SS. Initial evaluation of the LifeForce yoga program as a therapeutic intervention for depression. Int J Yoga Therap. 2008;18:49-57.
190. Pan NL, Jiang MJ, Poon PWF, Huang AM. The role of brain-derived neurotrophic factor in the antidepressant effects of Sudarshan Kriya Yoga. Master's thesis. 2006. Available from: http://ethesys.lib.ncku. edu.tw/ETD-db/ETD-search/view_etd?URN=etd-0808107-104238. Accessed October 18, 2012.
191. Manocha R, Black D, Sarris J, Stough C. A randomized, controlled trial of meditation for work stress, anxiety and depressed mood in full-time workers. Evid Based Complement Alternat Med. 2011; 2011:960583.
192. Kjellgren A, Bood SA, Axelsson K, Norlander T, Saatcioglu F. Wellness through a comprehensive Yogic breathing program - controlled pilot trial. BMC Complement Altern Med. 2007;7:43.
193. Mehta P, Sharma M. Yoga as a complementary therapy for clinical depression. Complement Health Pract Rev. 2010;15:156-170.
194. Eisendrath S, Chartier M, McLane M. Adapting mindfulness-based cognitive therapy for treatment-resistant depression. Cogn Behav Pract. 2011;18:362-370.
195. Plodek J. Reiki: an ancient therapy in modern times. In: Freeman L, editor. Mosby's Complementary and Alternative Medicine: A Research-Based Approach, 3rd ed; 2009.
196. Available from: http://nccam.nih.gov/health/reiki/introduction.htm. Accessed March 22, 2013.
197. Bowden D, Goddard L, Gruzelier J. A randomised controlled singleblind trial of the efficacy of Reiki at benefiting mood and well-being. Evid Based Complement Alternat Med. 2011;2011:381862.
198. Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. Arch Intern Med. 1999;159:2349-2356.
199. Craft L, Landers D. The effect of exercise on clinical depression and depression resulting from medical illness. A meta-analysis. J Sport Exerc Psychol. 1998;20:339-357.
200. Otto MW, Church TS, Craft LL, Greer TL, Smits JA, Trivedi MH. Exercise for mood and anxiety disorders. J Clin Psychiatry. 2007;68: 669-676.
201. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. Am J Prev Med. 2005;28:1-8.
202. Richardson CR, Avripas SA, Neal DL, Marcus SM. Increasing lifestyle physical activity in patients with depression or other serious mental illness. J Psychiatr Pract. 2005;11:379-388.
203. Koch S, Morlinghaus K, Fuchs T. The joy dance: specific effects of a single dance intervention on psychiatric patients with depression. Arts Psychother. 2007;34:340-349.
204. [No authors listed]. Available from: https://thequantumalliance.zendesk.com/entries/21055146-indigo-contraindications-for-biofeedback. Accessed April 8, 2013.
205. [No authors listed]. Available from: http://www.electrostimulateursmanuels.fr/fichiers/publications/Contraindications-et-Precautions/ contraindications.pdf. Accessed April 8, 2013.
206. Karavidas M, Lehrer P, Vaschillo E, et al. Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression. Appl Psychophysiol Biofeedback. 2007; 32(1):19-30.
207. Kim YHJ. The effectiveness of acupuncture for treating depression: a review. Alternative and Complementary Therapies. 2007.
208. Yeung AS, Ameral VE, Chuzi SE, Fava M, Mischoulon D. A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder. J Affect Disord. 2011;130:285-289.
209. Monti DA, Beitman BD, editors. Integrative Psychiatry. Oxford, UK: Oxford University Press; 2010.
210. Muskin PR, editor. Complementary and Alternative Medicine and Psychiatry. Arlington, VA: American Psychiatric Press Inc; 2000.
211. Mischoulan D, Rosenbaum JF. Natural Medications for Psychiatric Disorders, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
212. Ventegodt S, Merrick J. A review of side effects and adverse events of non-drug medicine (nonpharmaceutical complementary and alternative medicine): psychotherapy, mind-body medicine and clinical holistic medicine. J Complement Integr Med. 2009;6:16.
213. Mintz DL. Integrative approaches to depression and its treatment. Psychiatr Clin North Am. 2012;35:xiii-xvi.
214. Meyer B, Berger T, Caspar F, Beevers CG, Andersson G, Weiss M. Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. J Med Internet Res. 2009;11:e15.
215. van Straten A, Cuijpers P, Smits N. Effectiveness of a web-based self-help intervention for symptoms of depression, anxiety, and stress: randomized controlled trial. J Med Internet Res. 2008;25: 10:e7.
216. Warmerdam L, van Straten A, Twisk J, Riper H, Cuijpers P. Internet-based treatment for adults with depressive symptoms: randomized controlled trial. J Med Internet Res. 2008;10:e44.
217. Clarke G, Eubanks D, Reid E, et al. Overcoming Depression on the Internet (ODIN) (2): a randomized trial of a self-help depression skills program with reminders. J Med Internet Res. 2005;7:e16.
218. Hoek W, Schuurmans J, Koot HM, Cuijpers P. Prevention of depression and anxiety in adolescents: a randomized controlled trial testing the efficacy and mechanisms of Internet-based self-help problem-solving therapy. Trials. 2009;10:93.